Tharimmune Inc (THAR)

[BooDog]

$HILS .4702 Randy Milby - CEO & Chairman
Mr. Milby was the former Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. A seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.
https://finviz.com/quote.ashx?t=CRMD&p=d

HILS
https://finviz.com/quote.ashx?t=HILS&ty=c&ta=1&p=d

https://hillstreambio.com/pipeline/

https://hillstreambio.com/quatramer/

Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
https://hillstreambio.com/hillstream-biopharma-signs-exclusive-option-agreement-with-applied-biomedical-science-institute-absi-to-license-technology-for-her2-and-her3-to-be-developed-for-potential-treatments-against-drug-res/

I haven't been following HILS that long. And I'll be the first to tell you I'm no scientist or expert on drugs or thearapies. IF this venture works and can attack the solid tumors that will be a game changer imo. For me, this is where I look at risk/reward. Look back just to last Dec into January, this is back to testing those levels' Considering the fairly small float, I'm thinking if this gets the momentum into the beginning of trials with an IND filing this fall, well, this just may get there. Back over the $ that is.

cancer cells – causing them to rupture and stop replicating. An area of interest for the development of HSB-1216 are rare cancers with high unmet need.